Yes

Adrenergic Agonist Agent; Antihistamine, H₁ Blocker; Decongestant

Temporary relief of nasal congestion, running nose, sneezing, itching of nose or throat, and itchy, watery eyes due to the common cold, hay fever, or other respiratory allergies

C

Hypersensitivity to carbinoxamine or pseudoephedrine or any component; severe hypertension or coronary artery disease, MAO inhibitor therapy, GI or GU obstruction, narrow-angle glaucoma; avoid use in premature or term infants due to a possible association with SIDS

Narrow-angle glaucoma, bladder neck obstruction, symptomatic prostatic hypertrophy, asthmatic attack, and stenosing peptic ulcer

>10%:

Central nervous system: Slight to moderate drowsiness

Respiratory: Thickening of bronchial secretions

1% to 10%:

Central nervous system: Headache, fatigue, nervousness, dizziness

Gastrointestinal: Appetite increase, weight gain, nausea, diarrhea, abdominal pain, xerostomia

Neuromuscular & skeletal: Arthralgia

Respiratory: Pharyngitis

<1%: Edema, palpitations, depression, angioedema, photosensitivity, rash, hepatitis, myalgia, paresthesia, bronchospasm, epistaxis

Symptoms of overdose include dry mouth, flushed skin, dilated pupils, CNS depression

There is no specific treatment for an antihistamine overdose, however, most of its clinical toxicity is due to anticholinergic effects. Anticholinesterase inhibitors including physostigmine, neostigmine, pyridostigmine, and edrophonium may be useful by reducing acetylcholinesterase; for anticholinergic overdose with severe life-threatening symptoms, physostigmine 1-2 mg (0.5 mg or 0.02 mg/kg for children) I.V., slowly may be given to reverse these effects.

Increased toxicity: Barbiturates, TCAs, MAO inhibitors, ethanolamine antihistamines

Carbinoxamine competes with histamine for H₁-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract

Oral:

Drops: 1-18 months: 0.25-1 mL 4 times/day

Syrup:

18 months to 6 years: 2.5 mL 3-4 times/day

>6 years: 5 mL 2-4 times/day

Adults:

Liquid: 5 mL 4 times/day

Tablets: 1 tablet 4 times/day

Pseudoephedrine is a sympathomimetic which has potential to enhance vasoconstrictor effects of epinephrine; use local anesthetic with vasoconstrictor with caution

1% to 10% of patients will experience dry mouth which disappears with cessation of drug therapy

Take as directed; do not exceed recommended dose. Maintain adequate hydration (2-3 L/day of fluids unless instructed to restrict fluid intake). Avoid use of other depressants, alcohol, or sleep-inducing medications unless approved by prescriber. You may experience drowsiness, impaired coordination, blurred vision, or increased anxiety (use caution when driving or engaging in tasks requiring alertness until response to drug is known); or dry mouth or nausea (frequent small meals, frequent mouth care, chewing gum, or sucking hard candy may help). Report persistent dizziness, sedation, or agitation; difficulty breathing or increased cough; changes in urinary pattern; muscle weakness; or lack of improvement or worsening or condition. Pregnancy/breast-feeding precautions: Inform prescriber if you are or intend to be pregnant. Do not breast-feed.

Raise bed rails; institute safety measures; assist with ambulation

Drops: Carbinoxamine maleate 2 mg and pseudoephedrine hydrochloride 25 mg per mL (30 mL with dropper)

Syrup: Carbinoxamine maleate 4 mg and pseudoephedrine hydrochloride 60 mg per 5 mL (120 mL, 480 mL)

Tablet:

Film-coated: Carbinoxamine maleate 4 mg and pseudoephedrine hydrochloride 60 mg

Extended release: Carbinoxamine maleate 8 mg and pseudoephedrine hydrochloride 90 mg

Sustained release: Carbinoxamine maleate 8 mg and pseudoephedrine hydrochloride 120 mg